Related Experiment Videos
Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library
Natalia G Karasseva1, Vladislav V Glinsky, Ning X Chen
1Department of Biochemistry, University of Missouri, Columbia, 65211, USA.
Abstract:
The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. The overexpression of ErbB-2 in cancer cells as well as its extracellular accessibility makes it an attractive target for the development of tumor-specific agents. In this study, random peptide bacteriophage display technology was employed to identify peptides that bound the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity-selected phage population, was chemically synthesized and characterized for its binding activities to ErbB-2. The synthetic peptide exhibited high specificity for ErbB-2 and an equilibrium dissociation constant of 30 microM. Peptide binding to ErbB-2 positive human breast and prostate carcinoma cells was visualized in direct cell binding assays. In conclusion, the peptide KCCYSL has the potential to be developed into a cancer imaging or therapeutic agent targeting malignant cells overexpressing the ErbB-2 receptor.
Insights
Researchers identified a peptide, KCCYSL, that specifically binds to the ErbB-2 receptor. This peptide shows potential for developing targeted cancer therapies and imaging agents for ErbB-2-positive malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- The ErbB-2 receptor tyrosine kinase is overexpressed in several human cancers, making it a key target for therapeutic interventions.
- Its extracellular domain is accessible, presenting an opportunity for developing targeted cancer agents.
Purpose of the Study:
- To identify peptides that bind to the extracellular domain of the human ErbB-2 receptor using phage display technology.
- To characterize the binding specificity and affinity of the identified peptide for ErbB-2.
Main Methods:
- Random peptide bacteriophage display was used to screen for ErbB-2 binding peptides.
- The lead peptide, KCCYSL, was chemically synthesized and its binding to ErbB-2 was characterized.
- Direct cell binding assays were performed on ErbB-2-positive breast and prostate carcinoma cells.
Main Results:
- The peptide KCCYSL was identified as a high-affinity binder to ErbB-2.
- The synthetic peptide demonstrated high specificity for ErbB-2.
- Peptide binding was successfully visualized on ErbB-2-positive cancer cells.
Conclusions:
- The peptide KCCYSL has potential as a diagnostic or therapeutic agent for cancers overexpressing ErbB-2.
- This peptide could be developed into a targeted agent for cancer imaging or therapy.